Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $105.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 77.54% from the stock’s current price. A number […]